Top 5 Target	Count

OX2R(Orexin receptor type 2)	6
BDCA2(C-Type lectin domain family 4 member C)	2
CD3 x PDL1	1
LIGHT(Tumor necrosis factor superfamily member 14)	1
CD3(T cell surface glycoprotein CD3)	1

Drugs associated with Centessa Pharmaceuticals Plc

Lixivapatan

Target-

Mechanism-

Active Org.

Centessa Pharmaceuticals Plc

Originator Org.

Centessa Pharmaceuticals Plc

Active Indication

Polycystic Kidney, Autosomal Dominant

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date-

Imgatzumab

Target-

Mechanism-

Active Org.

Centessa Pharmaceuticals Plc

Originator Org.

Centessa Pharmaceuticals Plc

Active Indication

Cutaneous Squamous Cell Carcinoma

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

ORX-750

Target

OX2R

Mechanism

OX2R agonists

Active Org.

Centessa Pharmaceuticals Plc [+2]

Originator Org.

Nxera Pharma Co., Ltd.

Active Indication

Idiopathic Hypersomnia [+1]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Centessa Pharmaceuticals Plc

NCT07082829

/ RecruitingPhase 1

A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Start Date30 Jun 2025

Sponsor / Collaborator

Centessa Pharmaceuticals Plc

NCT06752668

/ RecruitingPhase 2

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)

Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
* IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. ORX750 is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.

Start Date23 Dec 2024

Sponsor / Collaborator

Centessa Pharmaceuticals Plc

NCT06568302

/ TerminatedPhase 3

A Global Open-label Extension Study to Observe the Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with hemophilia

Start Date11 Jul 2024

Sponsor / Collaborator

ApcinteX Ltd.

[+1]

100 Clinical Results associated with Centessa Pharmaceuticals Plc

0 Patents (Medical) associated with Centessa Pharmaceuticals Plc

Literatures (Medical) associated with Centessa Pharmaceuticals Plc

01 Mar 2024·Research and Practice in Thrombosis and Haemostasis

Coagulation and platelet biology at the intersection of health and disease: illustrated capsules of the 11th Symposium on Hemostasis at the University of North Carolina

Article

Author: Kolev, Krasimir ; Rezaie, Alireza R ; Flick, Matthew J ; Ünlü, Betül ; Baglin, Trevor ; Dayal, Sanjana ; O'Loghlen, Ana ; Gerber, Gloria ; Sparkenbaugh, Erica M ; Vercellotti, Gregory M ; Arepally, Gowthami M ; Buitrago, Lorena ; Stavrou, Evi X ; Davizon-Castillo, Pavel ; Aleman, Maria ; Hisada, Yohei

The University of North Carolina Symposia on Hemostasis began in 2002, with The First Symposium on Hemostasis with a Special Focus on FVIIa and Tissue Factor. They have occurred biannually since and have maintained the primary goal of establishing a forum for the sharing of outstanding advances made in the basic sciences of hemostasis. The 2024 11th Symposium on Hemostasis will bring together leading scientists from around the globe to present and discuss the latest research related to coagulation factors and platelet biology. In keeping with the tradition of the conference, we expect novel cross-disciplinary collaborations to result from bringing together fundamental scientists and physician-scientists from different backgrounds and perspectives. The aim of these collaborations is to springboard the next generation of important advances in the field. This year's program was designed to discuss Coagulation and Platelet Biology at the Intersection of Health and Disease. The goal is to develop a better understanding of the pathophysiologic mechanisms leading to hemostatic and thrombotic disorders as this understanding is critical for the continued development of safe and efficacious therapeutics. Included in this review article are illustrated capsules provided by our speakers that highlight the main conclusions of the invited talks.

10 Jan 2024·Science translational medicineQ1 · MEDICINE

Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension

Q1 · MEDICINE

Article

Author: Rhodes, Christopher J ; Chan, Stephen Y. ; El Khoury, Wadih ; Trembath, Richard C. ; Humbert, Marc ; Pauciulo, Michael W ; Boueiz, Adel ; Vargas, Sara O. ; Negi, Vinny ; Wu, Haodi ; Barndt, Robert J. ; Karnes, Jason H. ; Kaufman, Brett ; Tang, Ying ; McNamara, Dennis ; Tai, Yi-Yin ; Bhat, Bal ; Chau, B Nelson ; Vargas, Sara O ; Satoh, Taijyu ; Barndt, Robert J ; Nichols, William C ; Belmonte, Frances ; Sitbon, Olivier ; Wilkins, Martin R ; Corey, Catherine G ; Morrell, Nicholas W ; Kim, Seungchan ; Torrino, Stephanie ; Parikh, Victoria N ; Schwartz, Brian ; Morrell, Nicholas W. ; Yu, Qiujun ; Graf, Stefan ; Desai, Ankit A. ; Speyer, Gil ; Chan, Stephen Y ; Mari, Bernard ; Zhao, Jingsi ; Rhodes, Christopher J. ; Li, Gang ; Parikh, Victoria N. ; Gomez, Delphine ; Southgate, Laura ; Chau, B. Nelson ; Kelly, Neil J ; Al Aaraj, Yassmin ; Pauciulo, Michael W. ; Liu, Mingjun ; Wilkins, Martin R. ; Zhang, Yingze ; Trembath, Richard C ; Cho, Michael H. ; Wang, Bing ; Wang, Jianrong ; Bertero, Thomas ; Corey, Catherine G. ; Schwantes-An, Tae-Hwi ; Shiva, Sruti ; Nouraie, Mehdi ; Sun, Wei ; Nichols, William C. ; Cho, Michael H ; Okawa, Satoshi ; Lacoux, Caroline ; Kelly, Neil J. ; Karnes, Jason H ; Desai, Ankit A

Hypoxic reprogramming of vasculature relies on genetic, epigenetic, and metabolic circuitry, but the control points are unknown. In pulmonary arterial hypertension (PAH), a disease driven by hypoxia inducible factor (HIF)–dependent vascular dysfunction, HIF-2α promoted expression of neighboring genes, long noncoding RNA (lncRNA) histone lysine N -methyltransferase 2E-antisense 1 ( KMT2E-AS1 ) and histone lysine N-methyltransferase 2E ( KMT2E ). KMT2E-AS1 stabilized KMT2E protein to increase epigenetic histone 3 lysine 4 trimethylation (H3K4me3), driving HIF-2α–dependent metabolic and pathogenic endothelial activity. This lncRNA axis also increased HIF-2α expression across epigenetic, transcriptional, and posttranscriptional contexts, thus promoting a positive feedback loop to further augment HIF-2α activity. We identified a genetic association between rs73184087, a single-nucleotide variant (SNV) within a KMT2E intron, and disease risk in PAH discovery and replication patient cohorts and in a global meta-analysis. This SNV displayed allele (G)–specific association with HIF-2α, engaged in long-range chromatin interactions, and induced the lncRNA-KMT2E tandem in hypoxic (G/G) cells. In vivo, KMT2E-AS1 deficiency protected against PAH in mice, as did pharmacologic inhibition of histone methylation in rats. Conversely, forced lncRNA expression promoted more severe PH. Thus, the KMT2E-AS1 /KMT2E pair orchestrates across convergent multi-ome landscapes to mediate HIF-2α pathobiology and represents a key clinical target in pulmonary hypertension.

01 Jul 2021·Annals of the rheumatic diseasesQ1 · MEDICINE

Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma

Q1 · MEDICINE

Article

Author: Del Galdo, Francesco ; McKimmie, Clive S ; Distler, Jörg H W ; Migneco, Gemma ; El-Sherbiny, Yasser M ; Carr, Ian M ; Holmes, Steve ; Carriero, Antonio ; Wasson, Christopher W ; Ross, Rebecca L ; Antanaviciute, Agne ; Corinaldesi, Clarissa

Objectives:

Plasmacytoid dendritic cells (pDC) have been implicated in the pathogenesis of autoimmune diseases, such as scleroderma (SSc). However, this has been derived from indirect evidence using ex vivo human samples or mouse pDC in vivo. We have developed human-specific pDC models to directly identify their role in inflammation and fibrosis, as well as attenuation of pDC function with BDCA2-targeting to determine its therapeutic application.

Methods:

RNAseq of human pDC with TLR9 agonist ODN2216 and humanised monoclonal BDCA2 antibody, CBS004. Organotypic skin rafts consisting of fibroblasts and keratinocytes were stimulated with supernatant from TLR9-stimulated pDC and with CBS004. Human pDC were xenotransplanted into Nonobese diabetic/severe combined immunodeficiency (NOD SCID) mice treated with Aldara (inflammatory model), or bleomycin (fibrotic model) with CBS004 or human IgG control. Skin punch biopsies were used to assess gene and protein expression.

Results:

RNAseq shows TLR9-induced activation of human pDC goes beyond type I interferon (IFN) secretion, which is functionally inactivated by BDCA2-targeting. Consistent with these findings, we show that BDCA2-targeting of pDC can completely suppress in vitro skin IFN-induced response. Most importantly, xenotransplantation of human pDC significantly increased in vivo skin IFN-induced response to TLR agonist and strongly enhanced fibrotic and immune response to bleomycin compared with controls. In these contexts, BDCA2-targeting suppressed human pDC-specific pathological responses.

Conclusions:

Our data indicate that human pDC play a key role in inflammation and immune-driven skin fibrosis, which can be effectively blocked by BDCA2-targeting, providing direct evidence supporting the development of attenuation of pDC function as a therapeutic application for SSc.

186

News (Medical) associated with Centessa Pharmaceuticals Plc

12 Feb 2026

·www.biospace.com

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026. –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, powered by its unique NxWave™ GPCR structure-based drug discovery platform, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

11 Feb 2026

·www.biopharmadive.com

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

Today, a brief rundown of news from Evommune and Takeda Pharmaceutical, as well as updates from AstraZeneca, Upstream Bio and Moderna that you may have missed.Shares of Evommune nearly doubled on Tuesday following mid-stage study results the company reported in atopic dermatitis. Evommune said its drug, EVO301, led to a 33% placebo-adjusted improvement in a measure of disease severity after 12 weeks. That difference is potentially competitive with marketed biologics for eczema, among them Sanofi and Regenerons Dupixent, wrote William Blair analyst Matt Phipps. No severe side effects or treatment discontinuations were reported either. Evommunes drug neutralizes an inflammatory cytokine, IL-18, involved in inflammation. The company acquired it from South Korean biotech AprilBio in 2024, a year before going public. Ben FidlerThe Food and Drug Administration has agreed to evaluate an approval application for Takeda Pharmaceutical's “oveporexton,“ the lead member of a group of new, promising narcolepsy medicines. Takeda on Monday said the drug will receive a fast-track review, with an approval verdict slated for sometime between July and September. Like similar medicines from Alkermes, Eisai and Centessa Pharmaceuticals, oveporexton works by stimulating a protein known as orexin-2. In a report late last year, RBC Capital Markets argued that recent clinical data not only validate this emerging drug class, but suggest targeting orexin-2 “could have superior efficacy“ to existing therapies. Consensus among analysts, the RBC team added, is the class could generate more than $3.3 billion annually by 2034. Jacob BellAstraZeneca is advancing an experimental obesity pill following positive results in mid-stage testing. In its earnings report Tuesday, AstraZeneca said the drug, called elecoglipron and licensed from China-based Eccogene, met its primary goals in a pair of studies in diabetes and obesity. AstraZeneca didnt provide specifics, but said the results supported advancement into late-stage testing this year. AstraZeneca is well behind the leaders in obesity, but has used dealmaking to amass a portfolio of prospects. Ben FidlerUpstream Bios share price fell by more than 50% on Wednesday on Phase 2 study results for an asthma drug the company has positioned as a potential challenger to Amgen and AstraZenecas Tezspire. Upstream said that drug, verekitug, met its main objective by reducing annualized rates of disease exacerbations. It also helped improve measures of lung function. Still, Mizuho Securities analyst Joseph Catanzaro wrote that there was likely some disappointment from investors in the performance of a bi-yearly dosing regimen. The once-quarterly regimen is clearly active and viable, but Catanzaros team is not sure this dataset dispels concerns around emerging competition from others with similar drugs. Upstream is advancing verekitug into Phase 3 testing. Ben FidlerModerna has signed a five-year deal with the Mexican Government to boost the countrys health sovereignty and messenger RNA manufacturing capabilities. The agreement announced Monday will ensure Mexico has a stockpile of Modernas respiratory vaccines and includes a technology transfer deal equipping Mexican pharmaceutical company Liomont to produce the companys COVID shot domestically. Moderna will also work with the Mexican government on local clinical research and help with pandemic preparedness. Delilah Alvarado '

Clinical ResultPhase 3VaccineAcquisitionPhase 2

13 Jan 2026

·www.biospace.com

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognised as revenue in Q4 FY2025. -ENDS- About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, and powered by its unique NxWave™ GPCR structure-based drug discovery platform, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma QUVIVIQ™ is trademark of Idorsia Ltd. Enquiries: Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

100 Deals associated with Centessa Pharmaceuticals Plc

100 Translational Medicine associated with Centessa Pharmaceuticals Plc

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1

Phase 2

Phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lixivapatan	Polycystic Kidney, Autosomal Dominant More	Phase 3
ORX-750 ( OX2R )	Narcolepsy More	Phase 2
Imgatzumab	Cutaneous Squamous Cell Carcinoma More	Phase 2
CBS-004 ( BDCA2 )	Lupus Erythematosus, Cutaneous More	Preclinical
ORX-142 ( OX2R )	Neurodegenerative Diseases More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis